Skip to main content

Table 1 Patient Disposition (Safety Population)

From: The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis

 

Cariprazine

1.5–3 mg/d

n = 170

Cariprazine

4.5–6 mg/d

n = 361

Cariprazine

9 mg/d

n = 148

Cariprazine

Overall

N = 679

Completed, n (%)

70 (41.2)

154 (42.7)

48 (32.4)

272 (40.1)

Reasons for discontinuation, n (%)

 Adverse event

28 (16.5)

29 (8.0)

26 (17.6)

83 (12.2)

 Insufficient therapeutic response

1 (0.6)

11 (3.0)

13 (8.8)

25 (3.7)

 Protocol violation

13 (7.6)

31 (8.6)

10 (6.8)

54 (8.0)

 Withdrawal of consent

44 (25.9)

88 (24.4)

38 (25.7)

170 (25.0)

 Lost to follow-up

11 (6.5)

29 (8.0)

10 (6.8)

50 (7.4)

 Other reasons

3 (1.8)

19 (5.3)

3 (2.0)

25 (3.7)

Entered safety follow-up, (n)%

121 (71.2)

234 (64.8)

102 (68.9)

457 (67.3)